Products
Glucagon Biosimilar Recombinant Protein (Glucagon Receptor) for Research
Pre-Made Glucagon Biosimilar, Recombinant Protein targeting GCGR: Recombinant therapeutic protein targeting GGR/GL-R/MVAH is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Glucagon is a peptide hormone, produced by alpha cells of the pancreas. It raises concentration of glucose and fatty acids in the bloodstream, and is considered to be the main catabolic hormone of the body. It is also used as a medication to treat a number of health conditions. Its effect is opposite to that of insulin, which lowers extracellular glucose. It is produced from proglucagon, encoded by the GCG gene.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-857-1mg | 1mg | 3090 |
| GMP-Bios-INN-857-10mg | 10mg | |
| GMP-Bios-INN-857-100mg | 100mg | |
| GMP-Bios-INN-857-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Glucagon Biosimilar, Recombinant Protein targeting GCGR: Recombinant therapeutic protein targeting GGR/GL-R/MVAH |
| INN Name | Glucagon |
| Target | GCGR |
| Format | Recombinant Protein |
| Derivation | human |
| Species Reactivity | human |
| CH1 Isotype | GCG (glucagon) 1- 29 |
| VD LC | GCG (glucagon) 1- 29 |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | Eli Lilly (Indianapolis IN USA) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - GCGR
1. Protein Glucagon receptor
2. Gene GCGR
3. Organism Homo sapiens (Human)
Function
G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.
